Rotavirus Vaccine in Premature Babies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will establish the duration of excretion of rotavirus vaccine in stool following vaccination of premature babies hospitalised in a neonatal unit at the time of vaccination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates

NCT02010268

Enteropathy, Necrotizing Enterocolitis

COMPLETED NA

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

NCT03530124

Apnea Apnea Neonatal Prematurity

COMPLETED PHASE4

Antibiotic "Dysbiosis" in Preterm Infants

NCT02784821

Enterocolitis, Necrotizing Bacteremia Bronchopulmonary Dysplasia +4 more

COMPLETED PHASE2

What is the Impact of Early Life Exposures on the Cardiovascular System in Young Adulthood?

NCT01487824

Preterm Birth

COMPLETED

Early Predictors of Necrotizing Enterocolitis in Neonates

NCT03210831

Necrotizing Enterocolitis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rotavirus is the commonest cause of severe gastroenteritis in young children, and premature babies are at high risk of serious disease. The RV1 rotavirus vaccine is an altered form of the virus and is given to all children at 8 weeks and 12 weeks of age in the UK. It is given by mouth and excreted in the stool following vaccination - the vaccine virus can therefore be transmitted between people in the same way as the normal virus. Premature babies often receive their initial vaccines while they are still hospitalised in neonatal units. There are no data regarding stool excretion of the RV1 rotavirus vaccine in premature babies - there is a theoretical risk of transmission of the vaccine virus to other babies in the unit (if there was inadequate staff hand washing). Some countries have therefore advised against immunisation of babies while in the neonatal unit. In the UK, however, the vaccine is being given in neonatal units, enabling evaluation of the vaccine in hospitalised premature babies.

This is an observational study of babies admitted to the neonatal unit at the John Radcliffe Hospital, Oxford University Hospitals NHS Trust who receive their first dose of rotavirus vaccine during their hospital stay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroenteritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant's parent is willing and able to give informed consent for participation in the study.
* Current inpatient in the neonatal unit and expected to remain an inpatient for at least 14 days following immunisation with rotavirus vaccine.
* Due to receive rotavirus vaccination during their admission.
* Born at less than 37 completed weeks gestation (i.e. up to and including 36 weeks and 6 days)